Resources

Selected
  • 烽火通讯股价突破30元可能性分析
Type of publications
Regions
Diseases
446 results found
2025 ∙ Chen, J. Zhou, W. Cen, M. Chen, C. Cao, K. Chen, M. Qu, R. Miao, J. Qi, J. Wu, X. Zhang, H. Feng, Q. Dai, A. Zhou, J. Xu, N. Hu, X. Yang, S.
Effects of influenza vaccination on neurodegenerative and demyelinating disorders: a systematic review and meta-analysis
All age groups Influenza Efficacy/effectiveness Safety Administration
Rating:
Critically low
2025 ∙ Gyawali, R. Poudyal, N. Docherty, A.
Efficacy and Safety of Tetanus-Toxoid Conjugate Typhoid Vaccine (Vi-TT) in Children and Adolescents: A Systematic Review and Meta-Analysis
Newborn Children Adolescents Typhoid Efficacy/effectiveness Safety
Rating:
High
2025 ∙ Wu, P. C. Huang, I. H. Wang, C. W. Chung, W. H. Chen, C. B.
Erythema Multiforme and Epidermal Necrolysis Following COVID-19 Vaccines: A Systematic Review
All age groups COVID-19 Safety Administration
Rating:
Critically low
2025 ∙ Pan, Y. Jia, Z. Zhang, Y. Wu, Y. Jiang, J.
Estimates of the global prevalence of occult hepatitis B virus infection in population under 18 years old: a systematic review and meta-analysis
Newborn Children Adolescents Hepatitis B Efficacy/effectiveness Administration
Rating:
Critically low
2025 ∙ Williams, L. R. Hombach, J. Marti, M.
Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy
All age groups Herpes zoster Efficacy/effectiveness
Rating:
Critically low
2025 ∙ Zadeh Mehrizi, T. Eshrati, B. Ebrahimi Shahmabadi, H.
Evaluation of recent pre-booster studies on hepatitis B vaccine effectiveness across WHO regions with HBV prevalence above 1% in the general population up to 60 years of age: a systematic review
All age groups Hepatitis B Efficacy/effectiveness Administration
Rating:
Critically low
2025 ∙ Zhao, T. Xu, Q. Cai, X. Wang, M. Ao, L. Wei, T. Yang, H. Zhang, S. Zhang, X. Jin, S. Wang, X. Feng, X. Zhao, J. Wu, Y. Yang, J. Cui, F.
Global spatio-temporal distribution of coronavirus disease 2019 vaccine hesitancy between 2020 and 2022: A meta-analysis
Adults Older adults COVID-19 Acceptance
Rating:
Not applicable
2025 ∙ Zhang, C. Zhang, Y. Q. Liu, R. B. Ma, Y. T. Zhao, L. K. Yin, F. Q. Tu, J. Yao, Y. Y.
Growing attention of immunogenicity among patients with autoimmune diseases post-SARS-CoV-2 vaccination: meta-analysis and systematic reviews of the current studies
Adolescents Adults Older adults COVID-19 Efficacy/effectiveness
Rating:
Critically low
2025 ∙ Rivera-Izquierdo, M. Verdejo-Ianez, A. Morales-Portillo, A. Gonzalez-Alcaide, M. Lainez-Ramos-Bossini, A. J. Martinez-Ruiz, V. Fernandez-Martinez, N. F. Martin-delosReyes, L. M. Jimenez-Mejias, E. Guerrero-Fernandez de Alba, I. Valero-Ubierna, M. D. C. Lardelli-Claret, P. Schoenenberger-Arnaiz, J. A. Jimenez-Moleon, J. J.
High-dose versus standard-dose influenza vaccine for immunocompromised patients: A systematic review and meta-analysis of randomised clinical trials
Children Adolescents Adults Older adults Influenza Efficacy/effectiveness Safety Administration
Rating:
Low
2025 ∙ Brewer, S. K. Stefanos, R. Murthy, N. C. Asif, A. F. Stokley, S. Markowitz, L. E.
Human papillomavirus vaccination at age 9 or 10 years to increase coverage-a narrative review of the literature, United States 2014-2024
Americas United States of America Children Adolescents Human papillomavirus (HPV) Coverage
Rating:
Not applicable
Loading...